Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations

The panel provides insights on enhancing outcomes for patients with metastatic non-small cell lung cancer without targetable driver mutations.

EP: 1.Biomarker Testing and Guideline-Recommended Care in mNSCLC

EP: 2.Strategies to Increase Biomarker Testing Rates

EP: 3.Limitations on Optimal Biomarker Testing Rates

EP: 4.Impact of Biomarker Testing on Treatment Selection and Outcomes

EP: 5.Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC

EP: 6.NCCN Recommendations by PD-L1 Expression Level

EP: 7.Limitations of NCCN PD-L1 Expression Recommendations

EP: 8.Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC

EP: 9.Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC

EP: 10.Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response

EP: 11.Clinical Factors Impacting Immunotherapy Response and Optimizing Patient Selection

EP: 12.Overcoming Immunotherapy Resistance: Identifying Non-Responders and Novel Approaches

Now Viewing

EP: 13.Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations

Video content above is prompted by the following:

• Looking ahead, what is the most critical priority to meaningfully enhance outcomes for patients with metastatic non-small cell lung cancer without targetable driver mutations?

Related Videos

Related Content

Advertisement

November 18th 2024

FDA Approves Companion Diagnostic for Tepotinib in MET Exon 14 mNSCLC

Ashling Wahner

The FDA approved the FoundationOne Liquid CDx to identify patients with metastatic non–small cell lung cancer (mNSCLC) with MET exon 14 skipping alterations who may be eligible for tepotinib (Tepmetko; EMD Serono).

November 15th 2024

Tailored Management Needed for Male Patients With NSCLC After Surgery

Maggie L. Shaw

Lung cancer is the top cause of cancer-related death worldwide.

November 8th 2024

Sunvozertinib NDA Submitted to FDA for NSCLC

Chris Ryan

A new drug application (NDA) has been submitted to the FDA for sunvozertinib in pretreated EGFR exon 20–positive advanced non–small cell lung cancer (NSCLC).

October 30th 2024

Improving Early-Stage Lung Cancer Care

Maggie L. Shaw

More than 80% of patients with lung cancer receive care in their communities, but this can leave them vulnerable to gaps in care quality and delivery.

October 24th 2024

Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib

Maggie L. Shaw

Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.

October 18th 2024

Expanding Access to NSCLC Innovations: Challenges and Opportunities

Maggie L. Shaw

The current research focus for Umit Tapan, MD, Boston Medical Center, is reducing disparities in lung cancer care and improving treatment access, in particular for immunotherapy and targeted treatments.

Related Content

Advertisement

November 18th 2024

FDA Approves Companion Diagnostic for Tepotinib in MET Exon 14 mNSCLC

Ashling Wahner

The FDA approved the FoundationOne Liquid CDx to identify patients with metastatic non–small cell lung cancer (mNSCLC) with MET exon 14 skipping alterations who may be eligible for tepotinib (Tepmetko; EMD Serono).

November 15th 2024

Tailored Management Needed for Male Patients With NSCLC After Surgery

Maggie L. Shaw

Lung cancer is the top cause of cancer-related death worldwide.

November 8th 2024

Sunvozertinib NDA Submitted to FDA for NSCLC

Chris Ryan

A new drug application (NDA) has been submitted to the FDA for sunvozertinib in pretreated EGFR exon 20–positive advanced non–small cell lung cancer (NSCLC).

October 30th 2024

Improving Early-Stage Lung Cancer Care

Maggie L. Shaw

More than 80% of patients with lung cancer receive care in their communities, but this can leave them vulnerable to gaps in care quality and delivery.

October 24th 2024

Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib

Maggie L. Shaw

Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.

October 18th 2024

Expanding Access to NSCLC Innovations: Challenges and Opportunities

Maggie L. Shaw

The current research focus for Umit Tapan, MD, Boston Medical Center, is reducing disparities in lung cancer care and improving treatment access, in particular for immunotherapy and targeted treatments.